ERBB2 and breast cancer: Considering previous studies and our univariate and multivariate analyses in different stratifications of 975 HER2-negative breast cancer patients, we conclude that for HER2-negative cases undergoing NAC in the Chinese population, stratifying based on HR, particularly ER, can tailor more personalized treatment strategies for patients with varying HER2 statuses.